This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 3 for:    phase 3 randomized f-627
Previous Study | Return to List | Next Study

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

This study is currently recruiting participants.
See Contacts and Locations
Verified August 2017 by Generon (Shanghai) Corporation Ltd.
Sponsor:
Information provided by (Responsible Party):
Generon (Shanghai) Corporation Ltd.
ClinicalTrials.gov Identifier:
NCT02872103
First received: August 8, 2016
Last updated: August 22, 2017
Last verified: August 2017
  Purpose
This is a randomized, double-blind and placebo controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with stage II-IV breast cancer receiving chemotherapy treatment.

Condition Intervention Phase
Breast Cancer Neutropenia Drug: F-627 Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Resource links provided by NLM:


Further study details as provided by Generon (Shanghai) Corporation Ltd.:

Primary Outcome Measures:
  • The duration in days of grade 4 (severe) neutropenia observed in chemotherapy cycle 1 in comparison to Placebo [ Time Frame: The first of 4, 21 Day Chemotherapy Cycles, an average of 3 weeks ]
    Subjects will be randomized to F-627 or Placebo at 2:1 ratio. About 24 hours after chemotherapy, subjects will either receive 20mg fixed dose F-627 or Placebo. The subject's absolute neutrophil count (ANC) will be monitored each day post chemotherapy administration until the ANC level exceeds 2.0x10^9/L, then the value will be monitored every three days until the next chemotherapy cycle is entered. The duration of grade 4 neutropenia (ANC <0.5x10^9/L) in this cycle is the primary efficacy endpoint.


Secondary Outcome Measures:
  • The duration in days of grade 4 (severe) neutropenia (ANC < 0.5 × 10^9/L) for chemotherapy cycles 2, 3, and 4, and over all cycles. [ Time Frame: chemotherapy cycle 2-4, about 9 weeks ]
    The duration of severe neutropenia will be measured for each patient during chemotherapy cycle 2-4 and over all cycles. Each chemotherapy is expected to last 21 days.

  • The duration in days of grade 2 (mild), grade 3 (moderate) and 4 (severe) neutropenia for each chemotherapy cycle and over all cycles. [ Time Frame: 4 chemotherapy cycles, about 12 weeks ]
    The duration in days of mild, moderate and severe neutropenia will be recorded for 4 chemotherapy cycles. Grade 2 neutropenia is when a patient's ANC<1.5x10^9/L, Grade 3 neutropenia is when a patient's ANC<1.0x10^9/L, and Grade 4 neutropenia is when a patient's ANC <0.5x10^9/L.

  • The incidence rates of febrile neutropenia for each chemotherapy cycle and over all cycles. [ Time Frame: 4 chemotherapy cycles, about 12 weeks ]
    Febrile neutropenia is defined as a single oral temperature of ≥38.3°C (101°F) or a temperature of >38.0°C (100.4°F) sustained for >1 hour and ANC < 0.5 x 10^9/L

  • The incidence rates of grade 2, grade 3, and grade 4 neutropenia for all chemotherapy cycles. [ Time Frame: 4 chemotherapy cycles, about 12 weeks ]
    The incidence rate of grade 2, 3 and 4 neutropenia will be recorded for all 4 chemotherapy cycles.

  • The time in days to ANC recovery post nadir for each chemotherapy cycle and over all cycles; recovery defined as an ANC ≥ 2.0 × 10^9/L after the expected ANC nadir. [ Time Frame: 4 chemotherapy cycles, about 12 weeks ]
    The time to ANC recovery post nadir for each patient, for each of their chemotherapy cycles will be recorded. Recovery for this protocol is defined as achieving an ANC ≥ 2.0 × 10^9/L after the expected ANC nadir (expected nadir is typically 4-6 days post chemotherapy administration).

  • The depth of the ANC nadir for each chemotherapy cycle and over all cycles. [ Time Frame: 4 chemotherapy cycles, about 12 weeks ]
    The depth of ANC nadir for each cycle is the minimal ANC value for a patient in each chemotherapy cycle

  • The incidence rates of infections for each chemotherapy cycle and over all cycles. [ Time Frame: 4 chemotherapy cycles, about 12 weeks ]
    The incidence rate of infections for each arm of the study will be recorded for each and all 4 chemotherapy cycles.

  • The use of antibiotic and pain medications for each chemotherapy cycle and over all cycles. [ Time Frame: 4 chemotherapy cycles, about 12 weeks ]
    The incidence of antibiotic and pain medications use

  • ECG endpoints: Change-from-baseline heart rate, PR, QRS and QTcF intervals. Categorical outliers and T-wave morphology changes on treatment. [ Time Frame: 4 chemotherapy cycles, about 12 weeks ]
    Change-from-baseline heart rate, PR, QRS and QTcF intervals


Other Outcome Measures:
  • F-627 antibody formation [ Time Frame: chemotherapy cycles 2 to 4, about 9 weeks ]
    Analysis of serum samples from cycles 2 to 4 to determine if the formation of antibodies to F-627 are present and, if antibodies are present, to evaluate the biological effects.


Estimated Enrollment: 120
Study Start Date: August 2016
Estimated Study Completion Date: August 2018
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: F-627
F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.
Drug: F-627
F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
Placebo Comparator: Placebo
Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.
Drug: F-627
F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
Drug: Placebo
Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.

Detailed Description:

This is a randomized, multi-center, single dose, double-blind, placebo controlled phase III study of the efficacy and safety of once-per-cycle of F-627 in women with stage II-IV breast cancer who are receiving myelotoxic TA chemotherapy treatment (Taxotere (docetaxel) + Adriamycin(doxorubicin)). F-627 is designed to treat neutropenia, an abnormally low number of neutrophils (a type of white blood cell) in the blood. Neutropenia is often seen in cancer patients receiving myelotoxic chemotherapy.

The primary objective of this study is to evaluate the efficacy and safety of single fixed dose of F-627 in breast cancer patients experiencing myelotoxic chemotherapy in comparison to placebo. F-627 or placebo is to be administered subcutaneously 24 hours after chemotherapy in each 21-day cycle of chemotherapy treatment (up to 4 cycles). Patients randomized to placebo arm will receive F-627 except in cycle 1. The primary endpoint will be the duration of grade 4 (severe) neutropenia - the number of days in which the patient has had an absolute neutrophil count (ANC < 0.5 x 10^9/L) observed in chemotherapy cycle 1.

  Eligibility

Ages Eligible for Study:   18 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Show evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.
  2. Females ≥ 18 years of age and < 75 years of age.
  3. Diagnosed with Stage II-IV breast cancer.
  4. Subject is scheduled to undergo 4 cycles of TA chemotherapy (docetaxel, doxorubicin, 75, and 60 mg/m2, respectively).
  5. ECOG Performance status of ≤ 2.
  6. White Blood Cell count (WBC) ≥ 4.0 × 109/L, hemoglobin ≥ 11.5 g/dL and a platelet count ≥ 150 × 109/L.
  7. Demonstrate adequate renal, hepatic function (Liver function tests (ALT, AST, alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.
  8. All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.

Exclusion Criteria:

  1. Subject is <18 or ≥ 75 years of age.
  2. Disease progression has occurred while receiving a taxane regimen.
  3. Subject has undergone radiation therapy within 4 weeks of enrollment.
  4. Subject has undergone bone marrow or stem-cell transplantation.
  5. Subject has a history of prior malignancy other than breast cancer that is NOT in remission.
  6. Subjects that have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e. lithium) within 6 weeks of the screening period are excluded.
  7. Subject has had chemotherapy within 365 days of screening.
  8. Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, ECG test, or any other relevant test.
  9. History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.
  10. Unwillingness to participate in the study.
  11. Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.
  12. Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment.
  13. Any condition, which can cause splenomegaly.
  14. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.
  15. ALT, AST, alkaline phosphatase, total bilirubin ≥ 2.5 upper limit of normal.
  16. Subject with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.
  17. Women who are pregnant or breast-feeding.
  18. Subject known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.
  19. Subject with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.
  20. Subjects with Sickle Cell disease
  21. Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02872103

Contacts
Contact: Sussane Lautner, Ph.D Susanne.Lautner@covance.com
Contact: Katja Becker Katja.Becker@covance.com

Locations
United States, New Jersey
Covance Recruiting
Princeton, New Jersey, United States, 08540
Contact: Susanne Lautner       Susanne.Lautner@covance.com   
Sponsors and Collaborators
Generon (Shanghai) Corporation Ltd.
  More Information

Responsible Party: Generon (Shanghai) Corporation Ltd.
ClinicalTrials.gov Identifier: NCT02872103     History of Changes
Other Study ID Numbers: GC-627-04
Study First Received: August 8, 2016
Last Updated: August 22, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Breast Neoplasms
Neutropenia
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Agranulocytosis
Leukopenia
Leukocyte Disorders
Hematologic Diseases

ClinicalTrials.gov processed this record on September 21, 2017